EP1303499B1 - Tetrazole derivatives - Google Patents
Tetrazole derivatives Download PDFInfo
- Publication number
- EP1303499B1 EP1303499B1 EP01956515A EP01956515A EP1303499B1 EP 1303499 B1 EP1303499 B1 EP 1303499B1 EP 01956515 A EP01956515 A EP 01956515A EP 01956515 A EP01956515 A EP 01956515A EP 1303499 B1 EP1303499 B1 EP 1303499B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tetrazol
- formula
- compound
- xanthene
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention is concerned with 2H-tetrazole-5-yl-amide derivatives of the general formula wherein
- the glutamate-dependent stimulus receptors are divided into two main groups.
- the first main group forms ligand-controlled ion channels.
- the metabotropic glutamate receptors (mGluR) belong to the second main group and, furthermore, belong to the family of G-protein-coupled receptors. At present, eight different members of these mGluRs' are known and of these some even have sub-types. On the basis of structural parameters, the different second messager signalling pathways and the different affinity to low-molecular weight chemical compounds, these eight receptors can be sub-divided into three sub-groups:
- Ligands of metabotropic glutamate receptors belonging to the first group can be used for the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits, as well as chronic and acute pain.
- treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia.
- Further treatable indications are Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, opiate addiction, anxiety, vomiting, dyskinesia and depression.
- ALS amyotrophic lateral sclerosis
- dementia caused by AIDS
- eye injuries eye injuries
- retinopathy idiopathic parkinsonism or parkinsonism caused by medicaments
- glutamate-deficiency functions such as e.g. muscle spasms, convulsions, migraine,
- Objects of the present invention are compounds of formula I and their pharmaceutically acceptable salts per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of the compounds in accordance with the invention for the preparation of a medicament useful in the control or prevention of illnesses of the aforementioned kind.
- the following structures are encompassed from the scope of compounds of formula I: and wherein R 1 and R 2 are as defined in formula I above.
- Preferred compounds of formula I in the scope of the present invention are those, in which X signifies 2 hydrogen atoms not forming a bridge (formula IA).
- X signifies 2 hydrogen atoms not forming a bridge
- a preferred enbodiment of the present invention are further compounds of formula IA, IB, IC, ID and IE, wherein R 2 signifies hydrogen.
- the invention embraces all stereoisomeric forms in addition to the racemates.
- lower alkyl used in the present description denotes straight-chain or branched saturated hydrocarbon residues with 1- 7 carbon atoms, preferably with 1-4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl and the like.
- lower alkoxy denotes a lower alkyl residue in the sense of the foregoing definition bonded via an oxygen atom.
- cycloalkyl embraces cyclic alkylene groups with 3 to 7 carbon atoms.
- the pharmaceutically acceptable salts can be manufactured readily according to methods known per se and taking into consideration the nature of the compound to be converted into a salt.
- Inorganic or organic acids such as, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid or citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like are suitable for the formation of pharmaceutically acceptable salts of basic compounds of formula I.
- Compounds which contain the alkali metals or alkaline earth metals, for example sodium, potassium, calcium, magnesium or the like, basic amines or basic amino acids are suitable for the formation or pharmaceutically acceptable salts of acidic compounds.
- Scheme 1 gives an overview of the manufacture of the compounds of formula I.
- the manufacture of representative compounds of formula I is described in detail in examples 1 - 28.
- the starting material is known or may be prepared by known methods.
- the compounds of formula I may be prepared in conventional manner by methods, known in the art.
- the compounds of formula I and their pharmaceutically acceptable salts are, as already mentioned above, metabotropic glutamate receptor agonists and can be used for the treatment or prevention of acute and/or chronic neurological disorders, such as psychosis, schizophrenia, Alzheimer's disease, cognitive diorders and memory deficits, as well as acute and chronic pain.
- Other treatable indications are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia.
- Further treatable indications are Alzheimer's disease, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.
- glutamate-deficient functions such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.
- examples 1 - 28 show agonistic activities, as measured in the assay described below, of 10 ⁇ M or less, typically 1 ⁇ M or less, and ideally of 0.3 ⁇ M or less.
- Examples of such compounds are EC 50 ( ⁇ M) Example No. 0.220 1 0.180 2 0.100 7 0.045 8 2.000 9 0.170 10 0.470 24 1.390 25 0.190 27
- cDNA encoding for rat mGlula receptor obtained from Prof. S. Nakanishi (Kyoto, Japan) was transiently transfected into EBNA cells using a procedure described by Schlaeger & Christensen, 1998.
- [Ca 2+ ]i measurement were performed on mGlu1a transfected EBNA cells after incubation of the cells with Fluo-3 AM (0.5 ⁇ M final concentration) for 1 hour at 37°C followed by 4 washes with assay buffer (DMEM supplemented with Hank's salt and 20 mM HEPES).
- [Ca 2+ ] measurement were done using a fluorometric imaging plate reader (FLIPR, Molecular Devices Corporation, La Jolla, CA, USA). When compounds were evaluated as antagonists they were tested against 10 ⁇ M glutamate as agonist.
- the inhibition (antagonists) or activation (agonists) curves were fitted with a four parameter logistic equation giving EC 50 , IC 50 and Hill coefficient using the iterative non linear curve fitting software Origin (Microcal Software Inc., Northampton, MA, USA).
- the compounds of formula I and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations.
- the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.
- the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
- the compounds of formula I and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
- Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules.
- Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules.
- Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like.
- Adjuvants such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary.
- Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
- the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
- the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
- the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described.
- 5-Amino-2-methyl-2H-tetrazole is obtained from 5-aminotetrazole-monohydrate and methyl iodide by the method of R.A. Henri et al., J.Amer.Chem.Soc. 76, 923 (1954).
- 5-Amino-2-ethyl-2H-tetrazole is prepared according to the method of R.N.Butler et al., J.Chem.Res.Synopsis 1988,188.
- 9,10-Dihydro-anthracene-9-carbonyl chloride was obtained by the method described in May & Mosettig, J.Amer.Chem.Soc.; 70; 688, (1948).
- Tablets of the following composition are produced in a conventional manner: mg/Tablet Active ingredient 100 Powdered. lactose 95 White corn starch 35 Polyvinylpyrrolidone 8 Na carboxymethylstarch 10 Magnesium stearate 2 Tablet weight 250
- Tablets of the following composition are produced in a conventional manner: mg/Tablet Active ingredient 200 Powdered. lactose 100 White corn starch 64 Polyvinylpyrrolidone 12 Na carboxymethylstarch 20 Magnesium stearate 4 Tablet weight 400
- Capsules of the following composition are produced: mg/Capsule Active ingredient 50 5 Crystalline. lactose 60 Microcrystalline cellulose 34 Talc 5 Magnesium stearate 1 Capsule fill weight 150
- the active ingredient having a suitable particle size, the crystalline lactose and the microcrystalline cellulose are homogeneously mixed with one another, sieved and thereafter talc and magnesium stearate are admixed.
- the final mixture is filled into hard gelatine capsules of suitable size.
Abstract
Description
-
- R1
- signifies hydrogen, C1-7alkyl, -(CH2)n-CF3, -(CH2)n-CHF2,, -(CH2)n-CN, -(CH2)n-cycloalkyl, -(CH2)n-O-C1-7alkyl, -(CH2)n-O-cycloalkyl or -(CH2)n-C(O)O-C1-6-alkyl;
- R2
- signifies hydrogen, C1-7alkyl. C1-7alkoxy, halogen, -C(O)-C1-7alkyl, -C(O)OH, -C(O)O-C1-7-alkyl, -NR3R4 or -C(O)-NR3R4 and wherein R3 and R4 may be independently from each other hydrogen or C1-7alkyl;
- X
- signifies -O-, -S-, -CH2, -OCH2- or two hydrogen atoms not forming a bridge; and
- n
- signifies 0,1, 2, 3 or 4;
as well as with their pharmaceutically acceptable salts. - These compounds and their salts are novel and are distinguished by valuable therapeutic properties.
- It has been found that the compounds of general formula I are group 1 metabotropic glutamate receptor agonists (mGluR).
- In the central nervous system (CNS) the transmission of stimuli takes place by the interaction of a neurotransmitter, which is sent out by a neuron, with a neuroreceptor. L-glutamic acid, the most commonly occurring neurotransmitter in the CNS, plays a critical role in a large number of physiological processes. The glutamate-dependent stimulus receptors are divided into two main groups. The first main group forms ligand-controlled ion channels. The metabotropic glutamate receptors (mGluR) belong to the second main group and, furthermore, belong to the family of G-protein-coupled receptors. At present, eight different members of these mGluRs' are known and of these some even have sub-types. On the basis of structural parameters, the different second messager signalling pathways and the different affinity to low-molecular weight chemical compounds, these eight receptors can be sub-divided into three sub-groups:
- mGluR1 and mGluR5 belong to group I, mGluR2 and mGluR3 belong to group II and mGluR4, mGluR6, mGluR7 and mGluR8 belong to group III.
- Ligands of metabotropic glutamate receptors belonging to the first group can be used for the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits, as well as chronic and acute pain.
- Other treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, opiate addiction, anxiety, vomiting, dyskinesia and depression.
- Objects of the present invention are compounds of formula I and their pharmaceutically acceptable salts per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of the compounds in accordance with the invention for the preparation of a medicament useful in the control or prevention of illnesses of the aforementioned kind.
The following structures are encompassed from the scope of compounds of formula I: - Preferred compounds of formula I in the scope of the present invention are those, in which X signifies 2 hydrogen atoms not forming a bridge (formula IA).
The following are examples of such compounds: - N-(2-methyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
- N-(2-ethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
- N-(2-cyclopropylmethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
- N-(2-isopropyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
- 2,2-diphenyl-N-[2-(2,2,2-trifluoro-ethyl)-2H-tetrazol-5-yl]-acetamide,
- 2,2-diphenyl-N-(2-propyl-2H-tetrazol-5-yl)-acetamide,
- N-(2-methoxymethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
- N-(2-tert-butyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
- N-(2-difluoromethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
- N-(2-cyanomethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide and
- (5-diphenylacetylamino-tetrazol-2-yl)-acetic acid methyl ester.
- Compounds of formula I, wherein X signifies -O- (formula IB) are further preferred. Examples of such compounds are:
- 9H-xanthene-9-carboxylic acid (2-methyl-2H-tetrazol-5-yl)-amide,
- 9H-xanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide,
- 9H-xanthene-9-carboxylic acid (2-cyclopropylmethyl-2H-tetrazol-5-yl)-amide,
- 9H-xanthene-9-carboxylic acid (2-isopropyl-2H-tetrazol-5-yl)-amide,
- 9H-xanthene-9-carboxylic acid [2-(2,2,2-trifluoro-ethyl)-2H-tetrazol-5-yl]-amide,
- 9H-xanthene-9-carboxylic acid (2-propyl-2H-tetrazol-5-yl)-amide,
- 9H-xanthene-9-carboxylic acid (2-methoxymethyl-2H-tetrazol-5-yl)-amide,
- 9H-xanthene-9-carboxylic acid (2-tert-butyl-2H-tetrazol-5-yl)-amide,
- 9H-xanthene-9-carboxylic acid (2-difluoromethyl-2H-tetrazol-5-yl)-amide,
- 9H-xanthene-9-carboxylic acid (2-cyanomethyl-2H-tetrazol-5-yl)-amide,
- {5-[(9H-xanthene-9-carbonyl)-amino]-tetrazol-2-yl}-acetic acid methyl ester,
- (RS)-1-methoxy-9H-xanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide,
- (RS)-2-methoxy-9H-xanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide and
- (RS)-4-methoxy-9H-xanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide.
- Compounds of formula I, wherein X signifies -S- (formula IC) are further preferred, for example the following compound:
- 9H-thioxanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide.
- Further preferred are compounds of formula I, wherein X signifies -CH2- (formula ID), for example the following compound:
- 9,10-dihydro-anthracene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide.
- Preferred are further compounds of formula I, wherein X signifies -OCH2- (formula IE), for example the following compound:
- (RS)-6,11-dihydro-dibenzo[b,e]oxepine-11-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide.
- A preferred enbodiment of the present invention are further compounds of formula IA, IB, IC, ID and IE, wherein R2 signifies hydrogen.
- The invention embraces all stereoisomeric forms in addition to the racemates.
- The term "lower alkyl" used in the present description denotes straight-chain or branched saturated hydrocarbon residues with 1- 7 carbon atoms, preferably with 1-4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl and the like.
- The term "lower alkoxy" denotes a lower alkyl residue in the sense of the foregoing definition bonded via an oxygen atom.
- The term "cycloalkyl" embraces cyclic alkylene groups with 3 to 7 carbon atoms..
- The compounds of general formula I and their pharmaceutically acceptable salts can be manufactured by processes, which comprises
- a) reacting a compound of formula
and, if desired,
converting a functional group in a compound of formula I into another functional group and, if desired,
converting a compound of formula I into a pharmaceutically acceptable salt. - In accordance with process variant described above to a stirred solution of a compound of formula II, for example of 5-amino-2-methyl-2H-tetrazole, 5-amino-2-ethyl-2H-tetrazole or 5-amino-2-cydopropylmethyl-2H-tetrazole in dichloromethane in the presence of pyridine and DMAP (2,2-bis(hydroxymethyl)propionic acid) the corresponding compound of formula III, for example diphenylacetyl chloride or 9H-xanthene-9-carbonyl chloride is added. The reaction is carried out at about 0 °C
- The pharmaceutically acceptable salts can be manufactured readily according to methods known per se and taking into consideration the nature of the compound to be converted into a salt. Inorganic or organic acids such as, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid or citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like are suitable for the formation of pharmaceutically acceptable salts of basic compounds of formula I. Compounds which contain the alkali metals or alkaline earth metals, for example sodium, potassium, calcium, magnesium or the like, basic amines or basic amino acids are suitable for the formation or pharmaceutically acceptable salts of acidic compounds.
- Scheme 1 gives an overview of the manufacture of the compounds of formula I. The manufacture of representative compounds of formula I is described in detail in examples 1 - 28. The starting material is known or may be prepared by known methods. The compounds of formula I may be prepared in conventional manner by methods, known in the art.
- The substituents have the significances given earlier.
- The compounds of formula I and their pharmaceutically acceptable salts are, as already mentioned above, metabotropic glutamate receptor agonists and can be used for the treatment or prevention of acute and/or chronic neurological disorders, such as psychosis, schizophrenia, Alzheimer's disease, cognitive diorders and memory deficits, as well as acute and chronic pain. Other treatable indications are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are Alzheimer's disease, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.
- It has been shown that the compounds of examples 1 - 28 show agonistic activities, as measured in the assay described below, of 10 µM or less, typically 1 µM or less, and ideally of 0.3 µM or less.
- Examples of such compounds are
EC50 (µM) Example No. 0.220 1 0.180 2 0.100 7 0.045 8 2.000 9 0.170 10 0.470 24 1.390 25 0.190 27 - cDNA encoding for rat mGlula receptor obtained from Prof. S. Nakanishi (Kyoto, Japan) was transiently transfected into EBNA cells using a procedure described by Schlaeger & Christensen, 1998. [Ca2+]i measurement were performed on mGlu1a transfected EBNA cells after incubation of the cells with Fluo-3 AM (0.5 µM final concentration) for 1 hour at 37°C followed by 4 washes with assay buffer (DMEM supplemented with Hank's salt and 20 mM HEPES). [Ca2+] measurement were done using a fluorometric imaging plate reader (FLIPR, Molecular Devices Corporation, La Jolla, CA, USA). When compounds were evaluated as antagonists they were tested against 10 µM glutamate as agonist.
- The inhibition (antagonists) or activation (agonists) curves were fitted with a four parameter logistic equation giving EC50, IC50 and Hill coefficient using the iterative non linear curve fitting software Origin (Microcal Software Inc., Northampton, MA, USA).
- E.-J. Schlaeger and K. Christensen Transient gene expression in mammalian cells grown in serum-free suspension culture. Cytotechnology, 15: 1-13,1998.
- The compounds of formula I and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
- The compounds of formula I and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
- In addition, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- As mentioned earlier, medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
- The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and 700 mg per day.
- Finally, as mentioned earlier, the use of compounds of formula I and of pharmaceutically acceptable salts thereof for the production of medicaments, especially for the control or prevention of acute and/or chronic neurological disorders of the aforementioned kind, is also an object of the invention.
- To a stirred solution of 5-amino-2-methyl-2H-tetrazole (0.50 g, 5.05 mmol), pyridine (0.48 g, 6.06 mmol) and DMAP (0.06 g, 0.51 mmol) in dichloromethane (30 ml) was added at 0°C diphenylacetyl chloride (1.16 g, 5.05 mmol). Stirring was continued at RT for 2 h, the reaction mixture was poured into sat. NaHCO3 solution (50 ml) and extracted with dichloromethane (3 x 50 ml). The combined organic layers were washed with brine (70 ml), dried (Na2SO4) and evaporated. The crude product was crystallized from ethyl acetate/hexane to give the title compound (0.83 g, 56 %) as a white solid, m.p. 218 °C (dec.) and MS: m/e = 293.1 (M+H+).
- The title compound, white solid, m.p. 247 °C (dec.) and MS: m/e = 307.1 (M+) was prepared in accordance with the general method of example 1 from 5-amino-2-methyl-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 169-170 ° and MS: (neg. ions): m/e = 306.2 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-ethyl-2H-tetrazole and diphenylacetyl chloride.
- The title compound, white solid, m.p. 228 °C (dec.) and MS: (neg. ions): m/e = 320.0 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-ethyl-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 147-148° and MS: m/e = 334.3 (M++H) was prepared in accordance with the general method of example 1 from 5-amino-2-cyclopropylmethyl-2H-tetrazole and diphenylacetyl chloride.
- The title compound, white solid, m.p. 222-224 °C and MS: (neg. ions): m/e = 346.2 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-cyclopropylmethyl-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 175-177 ° and MS: (neg. ions): m/e = 320.2 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-isopropyl-2H-tetrazole and diphenylacetyl chloride.
- The title compound, white solid, MS: (neg. ions): m/e = 334.2 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-isopropyl-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 146-148° and MS: (neg. ions): m/e = 360.0 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-(2,2,2-triffuoroethyl)-2H-tetrazole and diphenylacetyl chloride.
- The title compound, white solid, m.p. 209-210° and MS: (neg. ions): m/e = 374.1 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-(2,2,2-trifluoroethyl)-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 124-125° and MS: (neg. ions): m/e = 320.0 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-propyl-2H-tetrazole and diphenylacetyl chloride.
- The title compound, white solid, m.p. 208-209 ° and MS: (neg. ions): m/e = 334.1 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-propyl-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 127-128 ° and MS: (neg. ions): m/e = 322.2 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-methoxymethyl-2H-tetrazole and diphenylacetyl chloride.
- The title compound, white solid, m.p. 221-222° and MS: (neg. ions): m/e = 336.1 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-methoxymethyl-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 191-192° and MS: (neg. ions): m/e = 334.3 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-tert-butyl-2H-tetrazole and diphenylacetyl chloride.
- The title compound, white solid, m.p. 230-231° and MS: (neg. ions): m/e = 348.2 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-tert-butyl-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 143-145 ° and MS: (neg. ions): m/e = 328.1 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-difluoromethyl-2H-tetrazole and diphenylacetyl chloride.
- The title compound, white solid, m.p. 168-169 ° and MS: (neg. ions): m/e = 342.0 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-difluoromethyl-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 173-174 ° and MS: m/e = 319.3 (M++H) was prepared in accordance with the general method of example 1 from (5-amino-tetrazol-2-yl)-acetonitrile and diphenylacetyl chloride.
- The title compound, white solid, m.p. 204-205 ° and MS: m/e = 333.2 (M++H) was prepared in accordance with the general method of example 1 from (5-amino-tetrazol-2-yl)-acetonitrile and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 168-169 ° and MS: (neg. ions): m/e = 350.2 (M+-H) was prepared in accordance with the general method of example 1 from (5-amino-tetrazol-2-yl)-acetic acid methyl ester and diphenylacetyl chloride.
- The title compound, white solid, m.p. 243-244 ° and MS: (neg. ions): m/e = 364.0 (M+-H) was prepared in accordance with the general method of example 1 from (5-amino-tetrazol-2-yl)-acetic acid methyl ester and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 206-207° and MS: (neg. ions): m/e = 318.3 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-ethyl-2H-tetrazole and 9,10-dihydro-anthracene-9-carbonyl chloride.
- The title compound, yellow solid, m.p. 158-159° and MS: (neg. ions): m/e = 334.1 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-ethyl-2H-tetrazole and 6,11-dihydro-dibenzo [b,e]oxepine-11-carbonyl chloride.
- The title compound, white solid, m.p. 228 °C (dec.) and MS: (neg. ions): m/e = 320.0 (M+-H) was prepared in accordance with the general method of example 1 from 5-amino-2-ethyl-2H-tetrazole and 9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 259-260 °C (dec.) and MS: (pos. ions): m/e = 352.3 (M++H) was prepared in accordance with the general method of example 1 from 5-amino-2-ethyl-2H-tetrazole and (RS)-1-methoxy-9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 208-210 °C (dec.) and MS: (pos. ions): m/e = 352.3 (M++H) was prepared in accordance with the general method of example 1 from 5-amino-2-ethyl-2H-tetrazole and (RS)-2-methoxy-9H-xanthene-9-carbonyl chloride.
- The title compound, white solid, m.p. 239-240 °C (dec.) and MS: (pos. ions): m/e = 352.3 (M++H) was prepared in accordance with the general method of example 1 from 5-amino-2-ethyl-2H-tetrazole and (RS)-4-methoxy-9H-xanthene-9-carbonyl chloride.
- 5-Amino-2-methyl-2H-tetrazole is obtained from 5-aminotetrazole-monohydrate and methyl iodide by the method of R.A. Henri et al., J.Amer.Chem.Soc. 76, 923 (1954).
- 5-Amino-2-ethyl-2H-tetrazole is prepared according to the method of R.N.Butler et al., J.Chem.Res.Synopsis 1988,188.
- 5-amino-2-cyclopropylmethyl-2H-tetrazole (amorphous white solid and MS: m/e = 139.1 (M+)) is similarly obtained from 5-aminotetrazole-monohydrate and cyclopropylmethyl iodide using the general method of R.N.Butler et al. (loc. cit.).
- 5-Amino-2-propyl-2H-tetrazole ( liquid; MS: m/e = 127.1 (M+)) is similarly obtained from 5-aminotetrazole-monohydrate and propyl iodide using the general method of R.N.Butler et al. (loc. cit.).
- 5-Amino-2-isopropyl-2H-tetrazole (liquid, MS: m/e = 127.1 (M+)) is similarly obtained from 5-aminotetrazole-monohydrate and isopropyl iodide using the general method of R.N.Butler et al. (loc. cit.).
- 5-Amino-2-tert-butyl-2H-tetrazole (white solid; m.p. =114-115°) is obtained from 5-aminotetrazole-monohydrate and O-tert-butyl-N,N'-dicyclohexylisourea, according to the general method described by R.A. Henry et al., J.Heterocycl.Chem. 13, 391 (1976).
- 5-Amino-2-cyclopropylmethyl-2H-tetrazole (amorphous white solid and MS: m/e = 139.1 (M+)) is similarly obtained from 5-aminotetrazole-monohydrate and cyclopropylmethyl iodide using the general method of R.N.Butler et al. (loc. cit.).
- 5-Amino-2-(2,2,2-trifluoroethyl)-2H-tetrazole (white solid; m.p. = 95-97°) is obtained from 5-aminotetrazole-monohydrate and 2,2,2-trifluoroethyl trifluoromethanesulfonate, in analogy to W.G. Reifenrath et al., J.Med.Chem. 23, 985 (1980).
- 5-Amino-2-methoxymethyl-2H-tetrazole (waxy solid; MS: m/e = 129.0 (M+)) is obtained from 5-aminotetrazole-monohydrate and chloromethyl methyl ether using the general method of R.N.Butler et al. (loc. cit.).
- 5-Amino-2-difluoromethyl-2H-tetrazole (liquid; MS: m/e = 136.0 (M++H)) is obtained from 5-aminotetrazole-monohydrate and chlorodifluormethane, in analogy to the method described by V.G. Poludnenko et al., Chem.Heterocycl.Comp. (Engl.Transl.) 20, 422 (1984).
- (5-Amino-tetrazol-2-yl)-acetonitrile (white solid; m.p.=105-106°) is obtained from 5-aminotetrazole-monohydrate and chloroacetonitrile, according to the method described by S.R. Buzilova et al., J.Org.Chem. USSR (Engl.Transl.) 25, 1375 (1989).(5-Amino-tetrazol-2-yl)-acetic acid methyl ester (white solid; m.p.=127-128°) is obtained from 5-aminotetrazole-monohydrate and methyl bromoacetate, in analogy to the method described by S.R. Buzilova et al. (loc.cit.).
- 9,10-Dihydro-anthracene-9-carbonyl chloride was obtained by the method described in May & Mosettig, J.Amer.Chem.Soc.; 70; 688, (1948).
- 6,11-Dihydro-dibenzo[b,e]oxepine-11-carbonyl chloride (waxy solid) was obtained by the method described in Kumazawa et al., J.Med.Chem. 37, 804 (1994).
- (RS)-4-Methoxy-9H-xanthene-9-carbonyl chloride was prepared according to general methods described in WO 9706178. 4-Methoxy-xanthene [J.Med.Chem., 32(10), 2357(1989)] was deprotonated with lithium diisopropylamide in tetrahydrofuran followed by treatment with carbon dioxide. The resulting (RS)-4-methoxy-9H-xanthene-9-carboxylic acid (white solid and MS: m/e = 256.0 (M+)) was chlorinated with oxalyl chloride in toluene/DMF and yielded after evaporation of the reagent and solvents, the crude acid chloride, which was directly used without further purification.
- (RS)-1-Methoxy-9H-xanthene-9-carbonyl chloride was similarly obtained by chlorination of (RS)-1-methoxy-9H-xanthene-9-carboxylic acid (white solid and MS: m/e = 257.1 (M++H) obtained from 1-methoxy-xanthene [J.Org.Chem., 22, 1644(1957)]).
- (RS)-2-Methoxy-9H-xanthene-9-carbonyl chloride was similarly obtained by chlorination of (RS)-2-methoxy-9H-xanthene-9-carboxylic acid (white solid and MS: m/e = 256.0 (M+) obtained from 2-methoxy-xanthene [J.Chem.Soc., 812(1956)].
- Tablets of the following composition are produced in a conventional manner:
mg/Tablet Active ingredient 100 Powdered. lactose 95 White corn starch 35 Polyvinylpyrrolidone 8 Na carboxymethylstarch 10 Magnesium stearate 2 Tablet weight 250 - Tablets of the following composition are produced in a conventional manner:
mg/Tablet Active ingredient 200 Powdered. lactose 100 White corn starch 64 Polyvinylpyrrolidone 12 Na carboxymethylstarch 20 Magnesium stearate 4 Tablet weight 400 - Capsules of the following composition are produced:
mg/Capsule Active ingredient 50 5 Crystalline. lactose 60 Microcrystalline cellulose 34 Talc 5 Magnesium stearate 1 Capsule fill weight 150 - The active ingredient having a suitable particle size, the crystalline lactose and the microcrystalline cellulose are homogeneously mixed with one another, sieved and thereafter talc and magnesium stearate are admixed. The final mixture is filled into hard gelatine capsules of suitable size.
Claims (18)
- Compounds of the general formulaR1 signifies hydrogen, C1-7-alkyl, -(CH2)n-CF3, -(CH2)n-CHF2,, -(CH2)n-CN, -(CH2)n-cycloalkyl, -(CH2)n-O-C1-7-alkyl, - (CH2)n-O-cycloalkyl or -(CH2)n-C(O)O-C1-7-alkyl;R2 signifies hydrogen, C1-7-alkyl, C1-7-alkoxy, halogen, -C(O)-C1-7alkyl, -C(O)OH, -C(O)O-C1-7-alkyl, -NR3R4 or -C(O)-NR3R4 and wherein R3 and R4 may be independently from each other hydrogen or C1-7alkyl;X signifies -0-, -S-, -CH2, -OCH2- or two hydrogen atoms not forming a bridge; andn signifies 0, 1, 2, 3 or 4;
as well as their pharmaceutically acceptable salts. - A compound of formula IA in accordance with claim 2, which is
N-(2-methyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
N-(2-ethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
N-(2-cyclopropylmethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
N-(2-isopropyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
2,2-diphenyl-N- [2-(2,2,2-trifluoro-ethyl)-2H-tetrazol-5-yl] -acetamide,
2,2-diphenyl-N-(2-propyl-2H-tetrazol-5-yl)-acetamide,
N-(2-methoxymethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
N-(2-tert-butyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
N-(2-difluoromethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide,
N-(2-ryanomethyl-2H-tetrazol-5-yl)-2,2-diphenyl-acetamide and (5-diphenylacetylamino-tetrazol-2-yl)-acetic acid methyl ester. - A compound of formula IB in accordance with claim 3, which compound is
9H-xanthene-9-carboxylic acid (2-methyl-2H-tetrazol-5-yl)-amide,
9H-xanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide,
9H-xanthene-9-carboxylic acid (2-cyclopropylmethyl-2H-tetrazol-5-yl)-amide,
9H-xanthene-9-carboxylic acid (2-isopropyl-2H-tetrazol-5-yl)-amide,
9H-xanthene-9-carboxylic acid [2-(2,2,2-trifluoro-ethyl)-2H-tetrazol-5-yl] -amide,
9H-xanthene-9-carboxylic acid (2-propyl-2H-tetrazol-5-yl)-amide,
9H-xanthene-9-carboxylic acid (2-methoxymethyl-2H-tetrazol-5-yl)-amide,
9H-xanthene-9-carboxylic acid (2-tert-butyl-2H-tetrazol-5-yl)-amide,
9H-xanthene-9-carboxylic acid (2-difluoromethyl-2H-tetrazol-5-yl)-amide,
9H-xanthene-9-carboxylic acid (2-cyanomethyl-2H-tetrazol-5-yl)-amide,
{5-[(9H-xanthene-9-carbonyl)-amino]-tetrazol-2-yl}-acetic acid methyl ester,
(RS)-1-methoxy-9H-xanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide,
(RS)-2-methoxy-9H-xanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide and
(RS)-4-methoxy-9H-xanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide. - A compound of formula IC in accordance with claim 4, which compound is 9H-thioxanthene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide.
- A compound of formula ID in accordance with claim 5, which compound is 9,10-dihydro-anthracene-9-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide.
- A compound of formula IE in accordance with claim 6, which compound is (RS)-6,11-dihydro-dibenzo[b,e]oxepine-11-carboxylic acid (2-ethyl-2H-tetrazol-5-yl)-amide.
- A compound of formula IA, IB, IC, ID or IE in accordance with claims 2-6, wherein R2 signifies hydrogen.
- A medicament comprising a compound of formula I according to any one of claims 1-12 as well as pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipients.
- A medicament in accordance with claim 13 for the control or prevention of acute and/or chronic neurological disorders such as restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest, hypoglycaemia, Alzheimer's disease, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, cognitive disorders, memory deficits, schizophrenia, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, acute and chronic pain, dyskinesia and depression.
- The use of compounds of formula I in accordance with anyone of claims 1-12 for the production of medicaments, containing a compound of formula I for the treatment of diseases relating to the mGlu receptor.
- A compound of formula I in accordance with claims 1-12 as well as pharmaceutically acceptable salts thereof for the control or prevention of acute and/or chronic neurological disorders.
- A process for the manufacture of compounds of formula I according to any one of claim 1-12 as well as of pharmaceutically acceptable salts thereof, which process comprises
reacting a compound of formula
and, if desired,
converting a functional group in a compound of formula I into another functional group and, if desired,
converting a compound of formula I into a pharmaceutically acceptable salt. - A compound in accordance with claims 1-12, when manufactured according to a process in accordance with claim 17.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01956515A EP1303499B1 (en) | 2000-07-13 | 2001-07-05 | Tetrazole derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00115170 | 2000-07-13 | ||
EP00115170 | 2000-07-13 | ||
PCT/EP2001/007692 WO2002006254A1 (en) | 2000-07-13 | 2001-07-05 | Tetrazole derivatives |
EP01956515A EP1303499B1 (en) | 2000-07-13 | 2001-07-05 | Tetrazole derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1303499A1 EP1303499A1 (en) | 2003-04-23 |
EP1303499B1 true EP1303499B1 (en) | 2006-07-12 |
Family
ID=8169240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01956515A Expired - Lifetime EP1303499B1 (en) | 2000-07-13 | 2001-07-05 | Tetrazole derivatives |
Country Status (19)
Country | Link |
---|---|
US (1) | US6399641B1 (en) |
EP (1) | EP1303499B1 (en) |
JP (1) | JP3971298B2 (en) |
KR (1) | KR100504292B1 (en) |
CN (1) | CN1214017C (en) |
AR (1) | AR029706A1 (en) |
AT (1) | ATE332895T1 (en) |
AU (2) | AU2001278472B2 (en) |
BR (1) | BR0112465A (en) |
CA (1) | CA2415673A1 (en) |
DE (1) | DE60121447T2 (en) |
DK (1) | DK1303499T3 (en) |
ES (1) | ES2267797T3 (en) |
MX (1) | MXPA03000221A (en) |
PA (1) | PA8521901A1 (en) |
PE (1) | PE20020409A1 (en) |
PT (1) | PT1303499E (en) |
WO (1) | WO2002006254A1 (en) |
ZA (1) | ZA200210157B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ545747A (en) | 2003-08-06 | 2010-06-25 | Senomyx Inc | T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
CA2558278A1 (en) * | 2004-03-05 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd. | Diaryl-substituted five-membered heterocycle derivative |
AU2006210513C1 (en) | 2005-02-04 | 2012-10-25 | Senomyx, Inc. | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
JP2009513672A (en) | 2005-10-31 | 2009-04-02 | ブレインセルス,インコーポレイティド | GABA receptor-mediated regulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
KR101387563B1 (en) | 2006-04-21 | 2014-04-25 | 세노믹스, 인코포레이티드 | Comestible compositions comprising high potency savory flavorants, and processes for producing them |
JP2009536669A (en) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | Neurogenesis by angiotensin regulation |
CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP2093234A1 (en) | 2008-02-08 | 2009-08-26 | Nutrinova Nutrition Specialties & Food Ingredients GmbH | Oligopeptides for use as taste modulators |
TWI429404B (en) | 2008-03-03 | 2014-03-11 | Senomyx Inc | Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1343827A (en) * | 1971-06-15 | 1974-01-16 | Science Union & Cie | Acylaminotetrazoles and process for preparing them |
DE4129742A1 (en) * | 1991-09-06 | 1993-03-11 | Bayer Ag | HETEROCYCLICALLY SUBSTITUTED CHINOLYLMETHOXY-PHENYLACETAMIDE |
GB9626151D0 (en) * | 1996-12-17 | 1997-02-05 | Lilly Industries Ltd | Pharmaceutical compounds |
JP2001525390A (en) * | 1997-12-10 | 2001-12-11 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | Anticonvulsants and central nervous system active bis (fluorophenyl) alkylamides |
US6548522B1 (en) * | 1999-10-12 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives |
-
2001
- 2001-06-27 US US09/892,994 patent/US6399641B1/en not_active Expired - Fee Related
- 2001-07-05 PT PT01956515T patent/PT1303499E/en unknown
- 2001-07-05 EP EP01956515A patent/EP1303499B1/en not_active Expired - Lifetime
- 2001-07-05 KR KR10-2003-7000350A patent/KR100504292B1/en not_active IP Right Cessation
- 2001-07-05 DK DK01956515T patent/DK1303499T3/en active
- 2001-07-05 JP JP2002512158A patent/JP3971298B2/en not_active Expired - Fee Related
- 2001-07-05 CA CA002415673A patent/CA2415673A1/en not_active Abandoned
- 2001-07-05 AU AU2001278472A patent/AU2001278472B2/en not_active Ceased
- 2001-07-05 ES ES01956515T patent/ES2267797T3/en not_active Expired - Lifetime
- 2001-07-05 WO PCT/EP2001/007692 patent/WO2002006254A1/en active IP Right Grant
- 2001-07-05 AT AT01956515T patent/ATE332895T1/en not_active IP Right Cessation
- 2001-07-05 BR BR0112465-0A patent/BR0112465A/en not_active IP Right Cessation
- 2001-07-05 AU AU7847201A patent/AU7847201A/en active Pending
- 2001-07-05 CN CNB018126987A patent/CN1214017C/en not_active Expired - Fee Related
- 2001-07-05 MX MXPA03000221A patent/MXPA03000221A/en active IP Right Grant
- 2001-07-05 DE DE60121447T patent/DE60121447T2/en not_active Expired - Fee Related
- 2001-07-10 PA PA20018521901A patent/PA8521901A1/en unknown
- 2001-07-11 PE PE2001000693A patent/PE20020409A1/en not_active Application Discontinuation
- 2001-07-12 AR ARP010103306A patent/AR029706A1/en unknown
-
2002
- 2002-12-13 ZA ZA200210157A patent/ZA200210157B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2001278472B2 (en) | 2006-08-03 |
CA2415673A1 (en) | 2002-01-24 |
DK1303499T3 (en) | 2006-10-30 |
CN1214017C (en) | 2005-08-10 |
KR100504292B1 (en) | 2005-07-28 |
PT1303499E (en) | 2006-11-30 |
ZA200210157B (en) | 2004-03-15 |
MXPA03000221A (en) | 2003-06-06 |
DE60121447T2 (en) | 2007-02-01 |
JP2004504308A (en) | 2004-02-12 |
US6399641B1 (en) | 2002-06-04 |
AR029706A1 (en) | 2003-07-10 |
US20020022648A1 (en) | 2002-02-21 |
EP1303499A1 (en) | 2003-04-23 |
PA8521901A1 (en) | 2002-04-25 |
WO2002006254A1 (en) | 2002-01-24 |
KR20030016390A (en) | 2003-02-26 |
CN1441791A (en) | 2003-09-10 |
ES2267797T3 (en) | 2007-03-16 |
DE60121447D1 (en) | 2006-08-24 |
BR0112465A (en) | 2003-07-22 |
ATE332895T1 (en) | 2006-08-15 |
PE20020409A1 (en) | 2002-05-21 |
JP3971298B2 (en) | 2007-09-05 |
AU7847201A (en) | 2002-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1303499B1 (en) | Tetrazole derivatives | |
EP1171423B1 (en) | Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands | |
AU2001278472A1 (en) | Tetrazole derivatives | |
EP1224163B1 (en) | Use of carbonylamino derivatives against cns disorders | |
IL172821A (en) | Imidazole derivatives , process for their preparation, medicaments containing them and use of the derivatives for the manufacture of medicaments for the treatment and prevention of mglur5 receptor mediated disorders | |
EP1395568B1 (en) | 4-aminopyrimidine derivatives | |
AU2003298195B2 (en) | Oxazoles as mGluR1 enhancer | |
US6803381B1 (en) | Carbamic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030213 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VIEIRA, ERIC Inventor name: JOLIDON, SYNESE Inventor name: WICHMANN, JUERGEN Inventor name: MUTEL, VINCENT |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60121447 Country of ref document: DE Date of ref document: 20060824 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20060403269 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20060929 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2267797 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20070413 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070731 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20080617 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20080624 Year of fee payment: 8 Ref country code: TR Payment date: 20080626 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20080708 Year of fee payment: 8 Ref country code: DE Payment date: 20080731 Year of fee payment: 8 Ref country code: ES Payment date: 20080708 Year of fee payment: 8 Ref country code: LU Payment date: 20080731 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20080616 Year of fee payment: 8 Ref country code: FI Payment date: 20080722 Year of fee payment: 8 Ref country code: FR Payment date: 20080707 Year of fee payment: 8 Ref country code: IE Payment date: 20080718 Year of fee payment: 8 Ref country code: IT Payment date: 20080724 Year of fee payment: 8 Ref country code: NL Payment date: 20080619 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20080616 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20080730 Year of fee payment: 8 Ref country code: SE Payment date: 20080708 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20080704 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060712 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20100105 |
|
BERE | Be: lapsed |
Owner name: F. *HOFFMANN-LA ROCHE A.G. Effective date: 20090731 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20090705 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20100201 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090705 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100105 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090705 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090705 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090706 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20090706 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090706 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100204 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090705 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090705 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090706 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090705 |